Abiopharma

New Form 144 - Perimeter Solutions, Inc. Filed: 2025-09-08 AccNo: 0001950047-25-006829 Size: 6 KB

DiPalma Sheila Marie 🔴 sold 566.4K shares (12 derivative) of COGNEX CORP (CGNX) at $65.90 ($28.2M) Transaction Date: Sep 05, 2025 | Filing ID: 000020

New Form F-4/A - BioNTech SE Filed: 2025-09-08 AccNo: 0001193125-25-198333 Size: 2 MB

New Form 144 - Mirum Pharmaceuticals, Inc. Filed: 2025-09-08 AccNo: 0001950047-25-006827 Size: 4 KB

Stern Sadie 🔴 sold 1.5K shares of DEXCOM INC (DXCM) at $80.00 Transaction Date: Sep 04, 2025 | Filing ID: 000251

Friedl-Naderer Johanna 🔴 sold 1.0K shares of Dyne Therapeutics, Inc. (DYN) at $13.41 Transaction Date: Sep 04, 2025 | Filing ID: 113545

New Form 8-K - Immix Biopharma, Inc. Filed: 2025-09-08 AccNo: 0001493152-25-012804 Size: 770 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item …

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics Strengthens Board of Directors with New Appointments

MACDONALD LAURA ANN 🔴 sold 272.8K shares (14 derivative) of COGNEX CORP (CGNX) at $90.50 ($12.5M) Transaction Date: Sep 05, 2025 | Filing ID: 000018

New Form 8-K - Adaptimmune Therapeutics PLC Filed: 2025-09-08 AccNo: 0001558370-25-011925 Size: 321 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

New Form 8-K/A - InspireMD, Inc. Filed: 2025-09-08 AccNo: 0001493152-25-012805 Size: 208 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)